NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $3.83 -0.11 (-2.79%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.74▼$4.0350-Day Range$2.92▼$4.3752-Week Range$2.13▼$7.73Volume360,677 shsAverage Volume517,452 shsMarket Capitalization$184.76 millionP/E Ratio11.61Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Puma Biotechnology alerts: Email Address Puma Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside82.8% Upside$7.00 Price TargetShort InterestBearish10.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 7 Articles This WeekInsider TradingSelling Shares$294,859 Sold Last QuarterProj. Earnings Growth31.82%From $0.22 to $0.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.98 out of 5 starsMedical Sector211th out of 936 stocksPharmaceutical Preparations Industry87th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.94% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 29.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 2.6 News and Social Media Coverage News SentimentPuma Biotechnology has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for PBYI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $294,859.00 in company stock.Percentage Held by Insiders23.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to grow by 31.82% in the coming year, from $0.22 to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 11.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 11.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 172.24.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Puma Biotechnology Stock (NASDAQ:PBYI)Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More PBYI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBYI Stock News HeadlinesJuly 20, 2024 | insidertrades.comMaximo F. Nougues Sells 4,156 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJuly 3, 2024 | insidertrades.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Sells 5,295 Shares of StockJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 26 at 8:42 PM | benzinga.comWhere Puma Biotechnology Stands With AnalystsJuly 19, 2024 | americanbankingnews.comPuma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 21,920 Shares of StockJuly 18, 2024 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial ResultsJuly 18, 2024 | americanbankingnews.comAnalyzing Gyre Therapeutics (NASDAQ:GYRE) and Puma Biotechnology (NASDAQ:PBYI)June 7, 2024 | businesswire.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…June 3, 2024 | businesswire.comPuma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung CancerJune 2, 2024 | businesswire.comPuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)May 28, 2024 | businesswire.comPuma Biotechnology to Join Russell 3000 IndexMay 26, 2024 | finance.yahoo.comWith 49% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) has piqued the interest of institutional investorsMay 23, 2024 | businesswire.comPuma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual MeetingMay 5, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For Puma Biotechnology, Inc. (NASDAQ:PBYI) After Its Latest ResultsMay 4, 2024 | finance.yahoo.comPuma Biotechnology First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Puma Biotechnology Amid Strong Q1 Performance and Promising OutlookMay 3, 2024 | finance.yahoo.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call TranscriptSee More Headlines Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+82.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.33 Trailing P/E Ratio11.61 Forward P/E Ratio17.41 P/E GrowthN/ANet Income$21.59 million Net Margins6.79% Pretax Margin7.29% Return on Equity35.49% Return on Assets7.26% Debt Debt-to-Equity Ratio1.07 Current Ratio1.46 Quick Ratio1.38 Sales & Book Value Annual Sales$235.60 million Price / Sales0.78 Cash Flow$0.71 per share Price / Cash Flow5.36 Book Value$1.12 per share Price / Book3.42Miscellaneous Outstanding Shares48,240,000Free Float36,806,000Market Cap$184.76 million OptionableOptionable Beta1.09 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alan H. Auerbach (Age 54)Founder, Chairman, President, CEO & Secretary Comp: $1.3MMr. Maximo F. Nougues (Age 55)CFO & Principal Accounting Officer Comp: $716.2kMr. Douglas Hunt B.Sc. (Age 59)FRAPS, Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer Comp: $598kMr. Jeffrey Jerome Ludwig (Age 58)Chief Commercial Officer Comp: $792.57kMr. Mariann OhanesianSenior Director of Investor RelationsKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTMarinus PharmaceuticalsNASDAQ:MRNSUroGen PharmaNASDAQ:URGNPhathom PharmaceuticalsNASDAQ:PHATIGM BiosciencesNASDAQ:IGMSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 120,104 shares on 7/26/2024Ownership: 0.641%Patriot Financial Group Insurance Agency LLCSold 6,600 shares on 7/26/2024Ownership: 0.023%Assenagon Asset Management S.A.Bought 70,060 shares on 7/18/2024Ownership: 0.291%Alan H AuerbachSold 21,920 sharesTotal: $81,104.00 ($3.70/share)Maximo F NouguesSold 4,156 sharesTotal: $15,377.20 ($3.70/share)View All Insider TransactionsView All Institutional Transactions PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $4.33 at the start of the year. Since then, PBYI stock has decreased by 11.5% and is now trading at $3.83. View the best growth stocks for 2024 here. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.12. The biopharmaceutical company had revenue of $43.80 million for the quarter, compared to analyst estimates of $41.53 million. Puma Biotechnology had a trailing twelve-month return on equity of 35.49% and a net margin of 6.79%. Who are Puma Biotechnology's major shareholders? Puma Biotechnology's top institutional shareholders include Bank of New York Mellon Corp (0.64%), Assenagon Asset Management S.A. (0.29%) and Patriot Financial Group Insurance Agency LLC (0.02%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Douglas M Hunt, Michael Patrick Miller and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL) and (KITE) (KITE). This page (NASDAQ:PBYI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBYI Stock Alerts